摘要
目的观察培美曲塞治疗50例晚期非小细胞肺癌（NSCLC）患者的疗效和毒副反应。方法收集2006年6月至2010年4月接受培美曲塞化疗的50例NSCLC患者,分为单药组13例和联合组37例。单药组：培美曲塞500mg/m2d1,q3w。联合组：培美曲塞500mg/m2d1,卡铂（AUC=5）d1,或顺铂25mg/m2d1~d3,或奈达铂80mg/m2d1,q3w。所有患者接受至少2个周期化疗。近期疗效评价采用RECIST1.0标准,毒副反应评价按照WHO毒性评定标准。生活质量评价参照孙燕提出的生活质量（QOL）评分表。结果 50例患者均可评价疗效,完全缓解（CR）2例,部分缓解（PR）7例,稳定（SD）22例,进展（PD）19例,有效率（RR）18.0%,疾病控制率（DCR）62.0%。生活质量改善率达58.0%。主要毒性反应为1~2级骨髓抑制和胃肠道反应,经对症处理后不影响化疗进行。结论以培美曲塞为主的化疗方案治疗晚期NSCLC疗效较好,可明显改善患者生活质量,且毒性反应轻,易于耐受。
Objective To observe the efficacy and toxicity of 50 cases of advanced non-small cell lung cancer patients treated by pemetrexed.Methods Single agent regimen： patients received pemetrexed 500 mg/m2 on day 1 with every 21 days.Combination regimen： patients received pemetrexed 500 mg/m2 on day 1 and carboplatin 300 mg/m2 on day 1 or cisplatin 35 mg/m2 on day 1 to day 3 or nedaplatin 80 mg/m2 on day 1 by intravenous infusion with 21 days as one cycle.RECIST 1.0 standard was used to evaluate clinical efficiency,and the WHO toxicity standard was used to evaluate toxic reaction,and the QOL was used to evaluate the quality of life.Results All patients were given 162 cycles（at least 2 cycles,at most 6 cycles） and the response rate of all the patients were evaluated.There were 2 complete remission（CR）,7 partial remission（PR）,22 stable disease（SD） and 19 progressive disease（PD） in the group,the overall response rate was（RR） 18.0% and disease control rate was（DCR） 62.0%.The quality of life improvement rate was 58.0%.The major toxic reaction included neutropenia,thrombocytopenia,hypemia,nausea,and vomiting.Most of the severity of these effects was grade1-2 and well tolerated.Conclusion Chemotherapy with pemetrexed or pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer is effective,safe and well-tolerable,which can improve the patient quality of life.
出处
《临床肿瘤学杂志》
CAS
2010年第10期900-903,共4页
Chinese Clinical Oncology
关键词
非小细胞肺癌
培美曲塞
化学治疗
Non-small cell lung cancer
Pemetrexed
Chemotherapy
